Abstract: The present invention provides polynucleotides encoding human and murine guanylate binding protein polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The present invention further relates to diagnostic and therapeutic methods for applying the guanylate binding protein polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, such as rheumatoid arthritis and/or conditions related to aberrant NF-?B activity, guanylate binding activity and GTPase activity. The present invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
Type:
Grant
Filed:
June 1, 2004
Date of Patent:
June 5, 2007
Assignee:
Bristol-Myers Squibb Company
Inventors:
Julie Carman, Stephen J. Warner, Rolf-Peter Ryseck
Abstract: The present invention includes an assay useful for identifying inhibitors of Hepatitis C virus (HCV) activity. Particularly, the present invention is directed to a dual HCV assay useful for high throughput screening that quantifies both the amount of HCV RNA replication inhibitory activity associated with a test compound and the amount of cytotoxicity associated with that test compound. The present invention also includes compounds discovered using this assay, compositions containing such compounds and methods of treating Hepatitis C by the administration of such compounds. The present invention also includes reporter assays using enzymes associated with HCV RNA replication, as well as a cell line having ATTC Accession No. PTA-4583.
Type:
Grant
Filed:
August 12, 2003
Date of Patent:
March 27, 2007
Assignee:
Bristol-Myers Squibb Company
Inventors:
Min Gao, Julie A. Lemm, Donald R. O'Boyle, Peter Nower, Karen Rigat, Jin-hua Sun
Abstract: The present invention relates to modulators of P2Y10. Various modulators are disclosed, including an antibody that binds specifically to P2Y10. The present invention also relates to methods of activating resting T lymphocytes and inhibiting the proliferation of activated T lymphocytes. Methods of upregulating trascription of P2Y10 mRNA in a resting T lymphocyte, methods of inducing expression of P2Y10 on the surface of a resting T lymphocyte and methods of activating a T lymphocyte are disclosed. Also disclosed are pharmaceuticals and methods of treating an immune disease.